Spots Global Cancer Trial Database for Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Official Title: Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412
Study ID: NCT02090127
Conditions
Interventions
Study Description
Brief Summary: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Detailed Description: This treatment protocol will serve as a mechanism to continue to provide ficlatuzumab to patient 0001-000412, who was previously enrolled under protocol P05538 and whom the investigator believes is deriving clinical benefit from ficlatuzumab treatment.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
START, San Antonio, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
